COMPASS Pathways
COMP360 · Psilocybin · Treatment-Resistant Depression
Company Overview
COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS is developing COMP360 psilocybin therapy, a proprietary synthetic formulation, as a treatment for treatment-resistant depression (TRD). Following two successful Phase 3 trials (COMP005 in June 2025 and COMP006 in February 2026), the company is preparing an NDA submission expected in Q4 2026; rolling submission may begin Q3 2026 after COMP006 Part B data. An IND for COMP202 (PTSD Phase 2b/3) was accepted by the FDA on January 7, 2026.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
COMP360 Synthetic psilocybin | Phase 3 | Treatment-Resistant Depression |
COMP360 Synthetic psilocybin | Phase 2b/3 | PTSD |
Key Financials
- Cash Position
- ~$280-300M
- Burn Rate
- ~$30-36M/quarter
- Last Reported
- Q4 2025 (est.)
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- Q3 2026Rolling NDA submission may begin after COMP006 Part B data readoutRegulatory
- Q4 2026Full NDA submission to FDA for COMP360 in Treatment-Resistant DepressionRegulatory
- H1 2026COMP202 Phase 2b/3 trial initiation for COMP360 in PTSD indicationClinical
Recent News
- 2026-02COMPASS raises $150M in equity offering; cash position approximately $280-300M post-offering
- 2026-02COMP006 Phase 3 trial meets primary endpoint in treatment-resistant depression
- 2026-01FDA accepts IND for COMP202 (COMP360 PTSD Phase 2b/3) on January 7, 2026
- 2025-06COMP005 Phase 3 trial meets primary endpoint — first successful psilocybin Phase 3 in TRD
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.